Zymeworks完成对 Theravance Biopharma的收购-动脉网

Zymeworks Completes Acquisition of Theravance Biopharma

GlobeNewswire 等信源发布 2026-09-23 20:01



可切换为仅中文







Conference call with Zymeworks management on September 28 at 8:30 am Eastern Time (ET)

9月28日美东时间上午8:30与Zymeworks管理层举行电话会议

VANCOUVER, British Columbia, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today completed the previously announced acquisition of Theravance Biopharma.

不列颠哥伦比亚省温哥华，2026年9月23日（环球社电）——生物技术公司Zymeworks Inc.（纳斯达克股票代码：ZYME）在管理其授权医疗资产组合的同时，致力于开发多样化的新型多功能生物治疗产品管线，该公司今日完成了此前宣布的对Theravance Biopharma的收购。

With the completion of the transaction, Theravance Biopharma is now part of Zymeworks, further advancing Zymeworks’ strategy to build a diversified revenue-generating biotechnology company, combining innovative R&D with growing commercial and royalty-based cash flows..

随着交易的完成，Theravance Biopharma 现已成为 Zymeworks 的一部分，进一步推进了 Zymeworks 打造多元化收入生物科技公司战略，将创新研发与不断增长的商业化和特许权使用费现金流相结合。

Zymeworks will host a conference call with investors and the general public at 8:30 am ET on Monday, September 28, to discuss the final transaction details of the acquisition. Dial-in details and webcast link are available on Zymeworks’ website at

Zymeworks 将于美东时间 9 月 28 日（星期一）上午 8:30 举办面向投资者和公众的电话会议，讨论此次收购的最终交易细节。拨入方式和网络直播链接可在 Zymeworks 网站获取，网址为

https://ir.zymeworks.com/events-and-presentations

. A replay of the webcast will be available within 24 hours following the conclusion of the call and will remain archived for a limited period.

网络直播的回放将在电话会议结束后24小时内提供，并将在有限时间内存档。

About Zymeworks Inc.

关于 Zymeworks 公司

Zymeworks is a global biotechnology company building a diversified portfolio of healthcare assets designed to generate durable cash flows while advancing innovative medicines for difficult-to-treat diseases. Zymeworks’ asset and royalty aggregation strategy combines a growing portfolio of commercial and near-commercial assets, including YUPELRI.

Zymeworks 是一家全球性生物技术公司，致力于构建多元化的医疗健康资产组合，旨在在推进针对难治疾病的创新药物研发的同时，创造持久的现金流。Zymeworks 的资产与特许权使用费整合战略结合了不断增长的商业化及接近商业化阶段的资产组合，其中包括 YUPELRI。

(revefenacin), with a differentiated internal research and development engine. Zymeworks’ portfolio also includes Ziihera

（雷夫那辛），并拥有差异化的内部研发引擎。Zymeworks的产品组合还包括Ziihera

(zanidatamab-hrii), a HER2-targeted bispecific antibody discovered and developed by Zymeworks and commercialized through global partnerships with Jazz Pharmaceuticals and BeOne Medicines, and pasritamig, a clinical-stage multispecific antibody developed by Johnson & Johnson using Zymeworks’ proprietary antibody engineering technologies..

(zanidatamab-hrii)，一种由Zymeworks发现并开发、并通过与Jazz Pharmaceuticals和BeOne Medicines的全球合作伙伴关系进行商业化的HER2靶向双特异性抗体，以及pasritamig，一种由强生公司利用Zymeworks专有的抗体工程技术开发的临床阶段多特异性抗体。

Zymeworks is advancing a diverse pipeline of novel biotherapeutics, leveraging its proprietary Azymetric™ platform and expertise in antibody-drug conjugates, multispecific antibodies and other next-generation antibody technologies. These capabilities, together with Zymeworks’ integrated drug development expertise, enable Zymeworks to develop differentiated therapeutics and create value through both internal innovation and strategic partnerships..

Zymeworks 正在推进多样化的新型生物治疗产品管线，依托其专有的 Azymetric™ 平台以及在抗体药物偶联物、多特异性抗体和其他下一代抗体技术方面的专业知识。这些能力，结合 Zymeworks 一体化的药物开发专长，使其能够通过内部创新和战略合作伙伴关系开发差异化的治疗产品并创造价值。

For more information about Zymeworks, its portfolio and pipeline, visit

欲了解更多关于 Zymeworks、其产品组合及研发管线的信息，请访问

www.zymeworks.com

and follow @ZymeworksInc on X.

并在 X 上关注 @ZymeworksInc。

Cautionary Note Regarding Forward-Looking Statements

关于前瞻性陈述的警示说明

This press release includes “forward-looking statements” or information within the meaning of the applicable securities legislation, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this press release include, but are not limited to, statements that relate to the anticipated benefits of the acquisition of Theravance Biopharma; the anticipated benefits of the financing in connection with the closing of the acquisition; anticipated milestone payments; completion of Theravance’s previously announced organizational restructuring; Zymeworks’ flexibility to invest in its R&D pipeline and pursue strategic opportunities while returning capital to stockholders; future growth of YUPELRI® sales and future royalty payments; contingent milestone payments due to Theravance Biopharma from the sale of Theravance Biopharma’s TRELEGY® royalty interests; Zymeworks’ expectations regarding implementation of its long-term strategy to maximize value creation; Zymeworks’ and its partners’ clinical development of product candidates; potential safety profile and therapeutic effects of product candidates; the commercial potential of technology platforms and product candidates; the anticipated benefits of its collaboration agreements; and other information that is not historical information.

本新闻稿包含适用证券立法（包括经修订的《1933年证券法》第27A条和经修订的《1934年证券交易法》第21E条）所定义的“前瞻性陈述”或信息。本新闻稿中的前瞻性陈述包括但不限于以下陈述：与收购Theravance Biopharma的预期收益相关的陈述；与完成该收购相关的融资的预期收益；预期的里程碑付款；完成Theravance此前宣布的组织重组；Zymeworks在向股东返还资本的同时，灵活投资于其研发管线并寻求战略机会的能力；YUPELRI®销售额的未来增长及未来的特许权使用费支付；因出售Theravance Biopharma在TRELEGY®中的特许权使用费权益而应向Theravance Biopharma支付的或有里程碑付款；Zymeworks对其实施长期战略以最大化价值创造的预期；Zymeworks及其合作伙伴对候选产品的临床开发；候选产品的潜在安全性特征和治疗效果；技术平台和候选产品的商业潜力；其合作协议的预期收益；以及其他非历史事实的信息。

When used herein, words such as “plan”, “believe”, “expect”, “may”, “continue”, “anticipate”, “potential”, “will”, “on track”, “progress”, “preserve”, “intend”, “could”, or the negative version of these words and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, per.

本文中使用的“计划”、“相信”、“预期”、“可能”、“继续”、“预计”、“潜在”、“将”、“进展顺利”、“进展”、“保持”、“打算”、“可以”等词语，以及这些词语的否定形式和类似表述，旨在识别前瞻性陈述。此外，任何提及预期、信念、计划、预测、目标、每

Factors that could cause Zymeworks’ actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to: financial closing procedures, final adjustments, and other developments; risks related to the financing in connection with the closing of the acquisition; any of Zymeworks’ or its partners’ product candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; uncertainties regarding the commercial success of YUPELRI.

可能导致 Zymeworks 实际结果与此类前瞻性陈述中明示或暗示的结果存在重大差异的因素包括但不限于：财务结账程序、最终调整及其他发展；与收购完成相关的融资风险；Zymeworks 或其合作伙伴的任何产品候选可能在开发过程中失败、未能获得所需的监管批准，或延迟至不再具有商业可行性的地步；以及关于 YUPELRI 商业成功的不确定性。

and TRELEGY

以及 TRELEGY

; the anticipated benefits of the acquisition may not be realized or will not be realized within the expected time period; TRELEGY

; 收购的预期收益可能无法实现，或无法在预期时间内实现；TRELEGY

may not achieve anticipated sales resulting in sales milestones not being met; Zymeworks may not achieve milestones or receive additional payments or royalties under its collaborations; regulatory agencies may impose additional requirements or delay the initiation of clinical trials; Ziihera

可能无法实现预期销售额，导致未能达成销售里程碑；Zymeworks 可能无法在其合作项目下达成里程碑或获得额外付款或特许权使用费；监管机构可能会施加额外要求或延迟临床试验的启动；Ziihera

may not be successfully commercialized; and the factors described under “Risk Factors” in Zymeworks’ quarterly and annual reports filed with the U.S. Securities and Exchange Commission and System for Electronic Document Analysis and Retrieval+ (copies of which may be obtained at www.sec.gov and

可能无法成功实现商业化；以及 Zymeworks 在向美国证券交易委员会和电子文档分析与检索系统（SEDAR+）提交的季度报告和年度报告中“风险因素”项下所述的因素（其副本可在 www.sec.gov 获取，

www.sedarplus.ca

）。

Although Zymeworks believes that such forward-looking statements are reasonable, there can be no assurance they will prove to be correct. Investors should not place undue reliance on forward-looking statements. The above assumptions, risks and uncertainties are not exhaustive. Forward-looking statements are made as of the date hereof and, except as may be required by law, Zymeworks undertakes no obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances, or to reflect the occurrences of unanticipated events..

尽管 Zymeworks 认为此类前瞻性陈述是合理的，但无法保证这些陈述将被证实为正确。投资者不应过度依赖前瞻性陈述。上述假设、风险和不确定性并非详尽无遗。前瞻性陈述仅截至本文发布日期作出，除非法律另有要求，Zymeworks 不承担更新、重新发布或修订任何前瞻性陈述以反映新信息、未来事件或情况，或反映意外事件发生的义务。

Contacts:

联系人：

Investor Inquiries:

投资者咨询：

Shrinal Inamdar

什里纳尔·伊南达尔

Vice President, Investor Relations

投资者关系副总裁

(604) 678-1388

ir@zymeworks.com

Media Inquiries:

媒体垂询：